Journal Article
. 2011 Aug; 12(9):852-61.
doi: 10.1016/S1470-2045(11)70214-5.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Karen A Gelmon 1 Marc Tischkowitz  Helen Mackay  Kenneth Swenerton  André Robidoux  Katia Tonkin  Hal Hirte  David Huntsman  Mark Clemons  Blake Gilks  Rinat Yerushalmi  Euan Macpherson  James Carmichael  Amit Oza  
Affiliations
  • PMID: 21862407
  •     430 citations

Abstract

Background: Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-negative breast cancer or high-grade serous and/or undifferentiated ovarian cancer.

Methods: In this phase 2, multicentre, open-label, non-randomised study, women with advanced high-grade serous and/or undifferentiated ovarian carcinoma or triple-negative breast cancer were enrolled and received olaparib 400 mg twice a day. Patients were stratified according to whether they had a BRCA1 or BRCA2 mutation or not. The primary endpoint was objective response rate by Response Evaluation Criteria In Solid Tumors (RECIST). All patients who received treatment were included in the analysis of toxic effects, and patients who had measurable lesions at baseline were included in the primary efficacy analysis. This trial is registered at ClinicalTrials.gov, number NCT00679783.

Findings: 91 patients were enrolled (65 with ovarian cancer and 26 breast cancer) and 90 were treated between July 8, 2008, and Sept 24, 2009. In the ovarian cancer cohorts, 64 patients received treatment. 63 patients had target lesions and therefore were evaluable for objective response as per RECIST. In these patients, confirmed objective responses were seen in seven (41%; 95% CI 22-64) of 17 patients with BRCA1 or BRCA2 mutations and 11 (24%; 14-38) of 46 without mutations. No confirmed objective responses were reported in patients with breast cancer. The most common adverse events were fatigue (45 [70%] of patients with ovarian cancer, 13 [50%] of patients with breast cancer), nausea (42 [66%] and 16 [62%]), vomiting (25 [39%] and nine [35%]), and decreased appetite (23 [36%] and seven [27%]).

Interpretation: Our study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clinical trials is needed.

Funding: AstraZeneca.

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Diana Nguyen, Maria Zajac-Kaye, +7 authors, Sherry X Yang.
Cell Cycle, 2011 Nov 22; 10(23). PMID: 22101337    Free PMC article.
Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?
Guo-Yan Liu, Wei Zhang.
Chin J Cancer, 2011 Dec 20; 31(1). PMID: 22176776    Free PMC article.
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
Jun-Xiang Zhang, Da-Qiang Li, +5 authors, Rakesh Kumar.
Hepatology, 2012 Jan 10; 55(6). PMID: 22223166    Free PMC article.
Major clinical research advances in gynecologic cancer in 2011.
Dong Hoon Suh, Kidong Kim, Jae Weon Kim.
J Gynecol Oncol, 2012 Feb 23; 23(1). PMID: 22355468    Free PMC article.
Advances in using PARP inhibitors to treat cancer.
Shivaani Kummar, Alice Chen, +4 authors, James H Doroshow.
BMC Med, 2012 Mar 10; 10. PMID: 22401667    Free PMC article.
Review.
The Valley of Death in anticancer drug development: a reassessment.
David J Adams.
Trends Pharmacol Sci, 2012 Mar 14; 33(4). PMID: 22410081    Free PMC article.
Review.
Molecular prescreening to select patient population in early clinical trials.
Jordi Rodón, Cristina Saura, +4 authors, Josep Tabernero.
Nat Rev Clin Oncol, 2012 Apr 05; 9(6). PMID: 22473105
Review.
Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.
Thomas Reiner, Jessica Lacy, +5 authors, Ralph Weissleder.
Neoplasia, 2012 Apr 13; 14(3). PMID: 22496617    Free PMC article.
Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment.
Alfonso Quintás-Cardama, Yi Hua Qiu, +4 authors, Steven M Kornblau.
Cancer, 2012 Apr 21; 118(21). PMID: 22517119    Free PMC article.
Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.
Sook Ryun Park, Alice Chen.
Hematol Oncol Clin North Am, 2012 Apr 24; 26(3). PMID: 22520984    Free PMC article.
Review.
Strategies for the discovery and development of therapies for metastatic breast cancer.
Bedrich L Eckhardt, Prudence A Francis, Belinda S Parker, Robin L Anderson.
Nat Rev Drug Discov, 2012 Jun 02; 11(6). PMID: 22653217
Highly Cited. Review.
Investigational agents in development for the treatment of ovarian cancer.
Shannon N Westin, Thomas J Herzog, Robert L Coleman.
Invest New Drugs, 2012 Jun 05; 31(1). PMID: 22661305    Free PMC article.
Review.
BRCAness: finding the Achilles heel in ovarian cancer.
Georgios Rigakos, Evangelia Razis.
Oncologist, 2012 Jun 08; 17(7). PMID: 22673632    Free PMC article.
Review.
The role of targeted therapy and biomarkers in breast cancer treatment.
Alison T Stopeck, Ursa Brown-Glaberman, +5 authors, Hope S Rugo.
Clin Exp Metastasis, 2012 Jun 14; 29(7). PMID: 22692561
Review.
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs.
Bryan A Gibson, W Lee Kraus.
Nat Rev Mol Cell Biol, 2012 Jun 21; 13(7). PMID: 22713970
Highly Cited. Review.
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Elena S Ratner, Alan C Sartorelli, Z Ping Lin.
Curr Opin Oncol, 2012 Jul 05; 24(5). PMID: 22759740    Free PMC article.
Review.
Role of PARP inhibitors in cancer biology and therapy.
D Davar, J H Beumer, L Hamieh, H Tawbi.
Curr Med Chem, 2012 Jul 14; 19(23). PMID: 22788767    Free PMC article.
Review.
Cancer treatment according to BRCA1 and BRCA2 mutations.
Kara N Maxwell, Susan M Domchek.
Nat Rev Clin Oncol, 2012 Jul 25; 9(9). PMID: 22825375
Review.
PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer.
Bristi Basu, Shahneen K Sandhu, Johann S de Bono.
Drugs, 2012 Jul 28; 72(12). PMID: 22834679
Review.
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Anneleen Daemen, Denise M Wolf, +12 authors, Laura J van't Veer.
Breast Cancer Res Treat, 2012 Aug 10; 135(2). PMID: 22875744    Free PMC article.
Clinical trials and future potential of targeted therapy for ovarian cancer.
Hiroaki Itamochi, Junzo Kigawa.
Int J Clin Oncol, 2012 Aug 29; 17(5). PMID: 22926640
Review.
BRCA1 and microRNAs: emerging networks and potential therapeutic targets.
Suhwan Chang, Shyam K Sharan.
Mol Cells, 2012 Sep 01; 34(5). PMID: 22936386    Free PMC article.
Review.
Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.
Fiona J Collinson, Jenny Seligmann, Timothy J Perren.
Curr Oncol Rep, 2012 Sep 06; 14(6). PMID: 22948277
Review.
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition.
Eddy S Yang, Somaira Nowsheen, +2 authors, Fen Xia.
Cancer Res, 2012 Sep 11; 72(21). PMID: 22962264    Free PMC article.
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, +17 authors, J S Lanchbury.
Br J Cancer, 2012 Oct 11; 107(10). PMID: 23047548    Free PMC article.
Highly Cited.
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
Guoyan Liu, Da Yang, +4 authors, Wei Zhang.
Pharmacogenomics, 2012 Oct 13; 13(13). PMID: 23057551    Free PMC article.
Review.
Update on triple-negative breast cancer: prognosis and management strategies.
Olivier Brouckaert, Hans Wildiers, Giuseppe Floris, Patrick Neven.
Int J Womens Health, 2012 Oct 17; 4. PMID: 23071421    Free PMC article.
Are there candidates for high-dose chemotherapy in ovarian carcinoma?
Renaud Sabatier, Anthony Gonçalves, +6 authors, Jean-Marc Extra.
J Exp Clin Cancer Res, 2012 Oct 18; 31. PMID: 23072336    Free PMC article.
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
Letizia Porcelli, Anna E Quatrale, +7 authors, Amalia Azzariti.
Mol Oncol, 2012 Nov 15; 7(3). PMID: 23148997    Free PMC article.
DNA repair dysregulation from cancer driver to therapeutic target.
Nicola J Curtin.
Nat Rev Cancer, 2012 Nov 24; 12(12). PMID: 23175119
Highly Cited. Review.
Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel.
Stephen R Armstrong, Rashmi Narendrula, +4 authors, Carita Lannér.
J Ovarian Res, 2012 Dec 01; 5(1). PMID: 23194409    Free PMC article.
Molecular pathways: targeting PARP in cancer treatment.
Khanh Do, Alice P Chen.
Clin Cancer Res, 2012 Dec 28; 19(5). PMID: 23269547    Free PMC article.
Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
Amanda Lovato, Lawrence Panasci, Michael Witcher.
Front Pharmacol, 2013 Jan 08; 3. PMID: 23293602    Free PMC article.
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Nigel Bundred, Janis Gardovskis, +8 authors, J Michael Dixon.
Invest New Drugs, 2013 Jan 15; 31(4). PMID: 23315029
Gene signatures in breast cancer: current and future uses.
Enrique Espinosa Arranz, Juan Ángel Fresno Vara, Angelo Gámez-Pozo, Pilar Zamora.
Transl Oncol, 2013 Jan 17; 5(6). PMID: 23323153    Free PMC article.
Advanced ovarian cancer: what should be the standard of care?
Barbara A Goff.
J Gynecol Oncol, 2013 Jan 25; 24(1). PMID: 23346317    Free PMC article.
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
Nicola J Curtin, Csaba Szabo.
Mol Aspects Med, 2013 Feb 02; 34(6). PMID: 23370117    Free PMC article.
Highly Cited. Review.
Treating breast cancer in the 21st century: emerging biological therapies.
Gabriel Tinoco, Sean Warsch, +2 authors, Alberto J Montero.
J Cancer, 2013 Feb 07; 4(2). PMID: 23386910    Free PMC article.
Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.
Greg M Thurber, Katy S Yang, +4 authors, Ralph Weissleder.
Nat Commun, 2013 Feb 21; 4. PMID: 23422672    Free PMC article.
Highly Cited.
Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.
Laurie Elit, Hal Hirte.
Onco Targets Ther, 2013 Mar 06; 6. PMID: 23459506    Free PMC article.
Systemic treatment for hereditary cancers: a 2012 update.
Evgeny N Imyanitov, Tomasz Byrski.
Hered Cancer Clin Pract, 2013 Apr 04; 11(1). PMID: 23548133    Free PMC article.
Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma.
Zi-Zhen Zhang, Yuan Jie Charles Liu, +3 authors, Xing-Zhi Ni.
World J Gastroenterol, 2013 Apr 10; 19(12). PMID: 23569343    Free PMC article.
Single cell analysis of drug distribution by intravital imaging.
Randy J Giedt, Peter D Koch, Ralph Weissleder.
PLoS One, 2013 Apr 18; 8(4). PMID: 23593370    Free PMC article.
Evidence for tankyrases as antineoplastic targets in lung cancer.
Alexander M Busch, Kevin C Johnson, +4 authors, Sarah J Freemantle.
BMC Cancer, 2013 Apr 30; 13. PMID: 23621985    Free PMC article.
Targeting signaling pathways in epithelial ovarian cancer.
Elisabeth Smolle, Valentin Taucher, +3 authors, Johannes Haybaeck.
Int J Mol Sci, 2013 May 07; 14(5). PMID: 23644885    Free PMC article.
Review.
Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs.
Kellie S Rath, Georgia A McCann, +3 authors, Karuppaiyah Selvendiran.
J Ovarian Res, 2013 May 15; 6(1). PMID: 23663277    Free PMC article.
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.
N J Curtin.
Br J Pharmacol, 2013 May 21; 169(8). PMID: 23682925    Free PMC article.
Review.
Methodological assessment of HCC literature.
G Daniele, N Costa, +3 authors, M Pirisi.
Ann Oncol, 2013 Jun 05; 24 Suppl 2. PMID: 23715943    Free PMC article.
Review.
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Maike Ihnen, Christine zu Eulenburg, +18 authors, Gottfried E Konecny.
Mol Cancer Ther, 2013 Jun 05; 12(6). PMID: 23729402    Free PMC article.
NAD⁺ metabolism: a therapeutic target for age-related metabolic disease.
Laurent Mouchiroud, Riekelt H Houtkooper, Johan Auwerx.
Crit Rev Biochem Mol Biol, 2013 Jun 08; 48(4). PMID: 23742622    Free PMC article.
Highly Cited. Review.
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
Aisling Pierce, Patricia M McGowan, +6 authors, Michael J Duffy.
Cancer Biol Ther, 2013 Jun 14; 14(6). PMID: 23760496    Free PMC article.
BRCA1 in the DNA damage response and at telomeres.
Eliot M Rosen.
Front Genet, 2013 Jun 27; 4. PMID: 23802008    Free PMC article.
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Joyce F Liu, Sara M Tolaney, +9 authors, Ursula A Matulonis.
Eur J Cancer, 2013 Jul 03; 49(14). PMID: 23810467    Free PMC article.
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
D H Moon, J-M Lee, +5 authors, E C Kohn.
Br J Cancer, 2013 Jul 23; 109(4). PMID: 23867999    Free PMC article.
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
Martin Köbel, Steve E Kalloger, +25 authors, Ovarian Tumor Tissue Analysis consortium.
Cancer Epidemiol Biomarkers Prev, 2013 Jul 25; 22(10). PMID: 23880734    Free PMC article.
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
Pavani Chalasani, Robert Livingston.
Oncologist, 2013 Jul 25; 18(8). PMID: 23881989    Free PMC article.
Review.
The management of early-stage and metastatic triple-negative breast cancer: a review.
Carey K Anders, Timothy M Zagar, Lisa A Carey.
Hematol Oncol Clin North Am, 2013 Aug 07; 27(4). PMID: 23915742    Free PMC article.
Review.
Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.
Foluso O Ademuyiwa, Matthew J Ellis, Cynthia X Ma.
J Oncol, 2013 Aug 29; 2013. PMID: 23983689    Free PMC article.
PARP inhibitors are not all equal.
Paul Dent.
Cancer Biol Ther, 2013 Sep 13; 14(10). PMID: 24025256    Free PMC article.
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.
Heather M Shaw, Marcia Hall.
Onco Targets Ther, 2013 Sep 18; 6. PMID: 24043945    Free PMC article.
Review.
DNA damage tolerance: a double-edged sword guarding the genome.
Gargi Ghosal, Junjie Chen.
Transl Cancer Res, 2013 Sep 24; 2(3). PMID: 24058901    Free PMC article.
Highly Cited.
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.
Silvana B De Lorenzo, Anand G Patel, Rachel M Hurley, Scott H Kaufmann.
Front Oncol, 2013 Sep 26; 3. PMID: 24062981    Free PMC article.
Review.
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Rebecca A Dent, Geoffrey J Lindeman, +7 authors, James Carmichael.
Breast Cancer Res, 2013 Sep 26; 15(5). PMID: 24063698    Free PMC article.
Highly Cited.
PARP inhibitors bounce back.
Ken Garber.
Nat Rev Drug Discov, 2013 Oct 02; 12(10). PMID: 24080684
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
Raquel E Reinbolt, John L Hays.
Front Oncol, 2013 Oct 08; 3. PMID: 24098868    Free PMC article.
Review.
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.
Christopher P Leamon, Chandra D Lovejoy, Binh Nguyen.
Pharmgenomics Pers Med, 2013 Oct 11; 6. PMID: 24109193    Free PMC article.
Review.
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.
Brian D Lehmann, Jennifer A Pietenpol.
J Pathol, 2013 Oct 12; 232(2). PMID: 24114677    Free PMC article.
Highly Cited. Review.
Appraising iniparib, the PARP inhibitor that never was--what must we learn?
Joaquin Mateo, Michael Ong, +2 authors, Johann S de Bono.
Nat Rev Clin Oncol, 2013 Oct 17; 10(12). PMID: 24129347
Review.
The significance of the alteration of 8-OHdG in serous ovarian carcinoma.
Xia Xu, Yan Wang, +4 authors, Kaijiang Liu.
J Ovarian Res, 2013 Oct 30; 6(1). PMID: 24165045    Free PMC article.
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
William Jacot, Simon Thezenas, +7 authors, Pierre-Jean Lamy.
BMC Cancer, 2013 Nov 07; 13. PMID: 24191908    Free PMC article.
Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
Christopher J Lord, Alan Ashworth.
Nat Med, 2013 Nov 10; 19(11). PMID: 24202391
Highly Cited. Review.
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
J-M Lee, J A Ledermann, E C Kohn.
Ann Oncol, 2013 Nov 15; 25(1). PMID: 24225019    Free PMC article.
Highly Cited. Review.
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, +13 authors, Elizabeth M Swisher.
Clin Cancer Res, 2013 Nov 19; 20(3). PMID: 24240112    Free PMC article.
Highly Cited.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Ilirjana Bajrami, Jessica R Frankum, +14 authors, Alan Ashworth.
Cancer Res, 2013 Nov 19; 74(1). PMID: 24240700    Free PMC article.
Highly Cited.
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Maria Saveria Gilardini Montani, Andrea Prodosmo, +6 authors, Silvia Soddu.
J Exp Clin Cancer Res, 2013 Nov 21; 32. PMID: 24252502    Free PMC article.
Clinical implications of using molecular diagnostics for ovarian cancers.
E C Kohn, S Romano, J-M Lee.
Ann Oncol, 2013 Dec 07; 24 Suppl 10. PMID: 24265398    Free PMC article.
Review.
New developments in the treatment of ovarian cancer--future perspectives.
J Lopez, S Banerjee, S B Kaye.
Ann Oncol, 2013 Dec 07; 24 Suppl 10. PMID: 24265409    Free PMC article.
Review.
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Suzanne A Eccles, Eric O Aboagye, +84 authors, Alastair M Thompson.
Breast Cancer Res, 2013 Nov 30; 15(5). PMID: 24286369    Free PMC article.
Highly Cited. Review.
Functional assays for analysis of variants of uncertain significance in BRCA2.
Lucia Guidugli, Aura Carreira, +8 authors, ENIGMA consortium.
Hum Mutat, 2013 Dec 11; 35(2). PMID: 24323938    Free PMC article.
Review.
Translational genomics in cancer research: converting profiles into personalized cancer medicine.
Lalit Patel, Brittany Parker, Da Yang, Wei Zhang.
Cancer Biol Med, 2013 Dec 19; 10(4). PMID: 24349831    Free PMC article.
Review.
Beyond DNA Repair: Additional Functions of PARP-1 in Cancer.
Alice N Weaver, Eddy S Yang.
Front Oncol, 2013 Dec 19; 3. PMID: 24350055    Free PMC article.
Review.
Targeting DNA damage response in cancer therapy.
Noriko Hosoya, Kiyoshi Miyagawa.
Cancer Sci, 2014 Feb 04; 105(4). PMID: 24484288    Free PMC article.
Highly Cited. Review.
Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.
Dong Zhou, Wenhua Chu, +5 authors, Robert H Mach.
Bioorg Med Chem, 2014 Feb 08; 22(5). PMID: 24503274    Free PMC article.
Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.
Ashwin R Sama, Russell J Schilder.
Int J Womens Health, 2014 Feb 11; 6. PMID: 24511245    Free PMC article.
Review.
New strategies for triple-negative breast cancer--deciphering the heterogeneity.
Ingrid A Mayer, Vandana G Abramson, Brian D Lehmann, Jennifer A Pietenpol.
Clin Cancer Res, 2014 Feb 19; 20(4). PMID: 24536073    Free PMC article.
Highly Cited. Review.
Genome-wide transcriptome profiling of homologous recombination DNA repair.
Guang Peng, Curtis Chun-Jen Lin, +12 authors, Shiaw-Yih Lin.
Nat Commun, 2014 Feb 21; 5. PMID: 24553445    Free PMC article.
Highly Cited.
BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
Melissa Burgess, Shannon Puhalla.
Front Oncol, 2014 Mar 01; 4. PMID: 24579064    Free PMC article.
Review.
DNA repair in cancer: emerging targets for personalized therapy.
Rachel Abbotts, Nicola Thompson, Srinivasan Madhusudan.
Cancer Manag Res, 2014 Mar 07; 6. PMID: 24600246    Free PMC article.
Review.
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Ryan P McMullin, Ben S Wittner, +11 authors, Dennis C Sgroi.
Breast Cancer Res, 2014 Mar 15; 16(2). PMID: 24625110    Free PMC article.
Better therapeutic trials in ovarian cancer.
Michael A Bookman, C Blake Gilks, +7 authors, Kenneth D Swenerton.
J Natl Cancer Inst, 2014 Mar 15; 106(4). PMID: 24627272    Free PMC article.
Review.
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Panagiotis A Konstantinopoulos, Andrew J Wilson, +2 authors, Dineo Khabele.
Gynecol Oncol, 2014 Mar 19; 133(3). PMID: 24631446    Free PMC article.
Emerging targeted combinations in the management of breast cancer.
Rebecca J Lee, Anne C Armstrong, Andrew M Wardley.
Breast Cancer (Dove Med Press), 2013 Jan 01; 5. PMID: 24648759    Free PMC article.
Review.
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
Ludmila Szabova, Sujata Bupp, +11 authors, Simone Difilippantonio.
PLoS One, 2014 Apr 22; 9(4). PMID: 24748377    Free PMC article.
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.
S Lindsey Davis, S Gail Eckhardt, John J Tentler, Jennifer R Diamond.
Ther Adv Med Oncol, 2014 May 03; 6(3). PMID: 24790649    Free PMC article.
Review.
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.
Young Eun Choi, Chiara Battelli, +6 authors, Panagiotis A Konstantinopoulos.
Oncotarget, 2014 May 07; 5(9). PMID: 24798692    Free PMC article.
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
Ciric To, Eun-Hee Kim, +5 authors, Karen T Liby.
Cancer Prev Res (Phila), 2014 May 13; 7(7). PMID: 24817481    Free PMC article.
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park.
J Surg Sci, 2014 May 13; 1(1). PMID: 24818173    Free PMC article.
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Eiji Kubota, Christopher T Williamson, +4 authors, D Gwyn Bebb.
Cell Cycle, 2014 May 21; 13(13). PMID: 24841718    Free PMC article.
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Jung-Min Lee, John L Hays, +12 authors, Elise C Kohn.
J Natl Cancer Inst, 2014 May 21; 106(6). PMID: 24842883    Free PMC article.
Highly Cited.
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
Monjri M Shah, Zachary C Dobbin, +6 authors, Charles N Landen.
Gynecol Oncol, 2014 May 23; 134(2). PMID: 24844596    Free PMC article.
First-line and maintenance therapy for ovarian cancer: current status and future directions.
Antonio González-Martín, Luisa Sánchez-Lorenzo, +2 authors, Luis Chiva.
Drugs, 2014 May 23; 74(8). PMID: 24848752
Review.
Resurrected cancer drug faces regulators.
Heidi Ledford.
Nature, 2014 Jun 27; 510(7506). PMID: 24965630
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
G Del Conte, C Sessa, +8 authors, L Gianni.
Br J Cancer, 2014 Jul 16; 111(4). PMID: 25025963    Free PMC article.
Subtyping of triple-negative breast cancer: implications for therapy.
Vandana G Abramson, Brian D Lehmann, Tarah J Ballinger, Jennifer A Pietenpol.
Cancer, 2014 Jul 22; 121(1). PMID: 25043972    Free PMC article.
Highly Cited. Review.
BRCA1 pathway function in basal-like breast cancer cells.
Sarah J Hill, Allison P Clark, Daniel P Silver, David M Livingston.
Mol Cell Biol, 2014 Aug 06; 34(20). PMID: 25092866    Free PMC article.
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Johnathan A Watkins, Sheeba Irshad, Anita Grigoriadis, Andrew N J Tutt.
Breast Cancer Res, 2014 Aug 06; 16(3). PMID: 25093514    Free PMC article.
Highly Cited. Review.
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Taofeek K Owonikoko, Guojing Zhang, +16 authors, Shi-Yong Sun.
Cancer Med, 2014 Aug 16; 3(6). PMID: 25124282    Free PMC article.
Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.
Marine Gilabert, Simon Launay, +12 authors, Anthony Gonçalves.
PLoS One, 2014 Aug 22; 9(8). PMID: 25144364    Free PMC article.
Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
Kimiyo N Yamamoto, Kouji Hirota, Shunichi Takeda, Hiroshi Haeno.
PLoS One, 2014 Aug 27; 9(8). PMID: 25158060    Free PMC article.
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Joyce F Liu, William T Barry, +16 authors, Ursula A Matulonis.
Lancet Oncol, 2014 Sep 15; 15(11). PMID: 25218906    Free PMC article.
Highly Cited.
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.
Yan Sun, Limei Hu, +12 authors, Wei Zhang.
J Pathol, 2014 Sep 18; 235(1). PMID: 25230372    Free PMC article.
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
J L Meisel, D M Hyman, +12 authors, D R Spriggs.
Ann Oncol, 2014 Oct 05; 25(12). PMID: 25281711    Free PMC article.
An update on PARP inhibitors--moving to the adjuvant setting.
Amir Sonnenblick, Evandro de Azambuja, Hatem A Azim, Martine Piccart.
Nat Rev Clin Oncol, 2014 Oct 08; 12(1). PMID: 25286972
Highly Cited. Review.
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
Daniela Luvero, Andrea Milani, Jonathan A Ledermann.
Ther Adv Med Oncol, 2014 Oct 25; 6(5). PMID: 25342990    Free PMC article.
Review.
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.
Kim A Reiss, Joseph M Herman, +13 authors, Nilofer S Azad.
Clin Cancer Res, 2014 Oct 31; 21(1). PMID: 25355929    Free PMC article.
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, +13 authors, Susan M Domchek.
J Clin Oncol, 2014 Nov 05; 33(3). PMID: 25366685    Free PMC article.
Highly Cited.
Molecular Heterogeneity of Triple Negative Breast Cancer.
Vandana G Abramson, Ingrid A Mayer.
Curr Breast Cancer Rep, 2014 Nov 25; 6(3). PMID: 25419441    Free PMC article.
Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.
Zongxiang Zhou, Manishha Patel, +6 authors, Jun Liu.
BMC Cancer, 2014 Dec 17; 14. PMID: 25495526    Free PMC article.
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Daniel Morgensztern, Meghan J Campo, +21 authors, Ramaswamy Govindan.
J Thorac Oncol, 2014 Dec 24; 10(1 Suppl 1). PMID: 25535693    Free PMC article.
Olaparib: first global approval.
Emma D Deeks.
Drugs, 2015 Jan 27; 75(2). PMID: 25616434
Review.
Surgery in the era of the 'omics revolution.
A D Beggs, M P Dilworth.
Br J Surg, 2015 Jan 30; 102(2). PMID: 25627134    Free PMC article.
Review.
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
Raphael Ceccaldi, Kevin W O'Connor, +4 authors, Panagiotis A Konstantinopoulos.
Cancer Res, 2015 Jan 31; 75(4). PMID: 25634215    Free PMC article.
Triple-negative breast cancer: new perspectives for targeted therapies.
Federica Tomao, Anselmo Papa, +6 authors, Silverio Tomao.
Onco Targets Ther, 2015 Feb 06; 8. PMID: 25653541    Free PMC article.
Highly Cited. Review.
New perspectives on targeted therapy in ovarian cancer.
Jermaine Ig Coward, Kathryn Middleton, Felicity Murphy.
Int J Womens Health, 2015 Feb 14; 7. PMID: 25678824    Free PMC article.
Review.
NF-κB signaling mediates acquired resistance after PARP inhibition.
Yuko Nakagawa, Anna S Sedukhina, +9 authors, Ko Sato.
Oncotarget, 2015 Feb 18; 6(6). PMID: 25686825    Free PMC article.
An update on PARP inhibitors for the treatment of cancer.
Sarah Benafif, Marcia Hall.
Onco Targets Ther, 2015 Mar 10; 8. PMID: 25750544    Free PMC article.
Review.
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Clare L Scott, Elizabeth M Swisher, Scott H Kaufmann.
J Clin Oncol, 2015 Mar 18; 33(12). PMID: 25779564    Free PMC article.
Highly Cited. Review.
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Robert L Coleman, Michael W Sill, +8 authors, Elizabeth M Swisher.
Gynecol Oncol, 2015 Mar 31; 137(3). PMID: 25818403    Free PMC article.
Highly Cited.
Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
Olga Karginova, Marni B Siegel, +15 authors, Carey K Anders.
Mol Cancer Ther, 2015 Apr 01; 14(4). PMID: 25824335    Free PMC article.
Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines.
A A Joy, M Ghosh, R Fernandes, M J Clemons.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848337    Free PMC article.
Review.
Regulators of homologous recombination repair as novel targets for cancer treatment.
Małgorzata Krajewska, Rudolf S N Fehrmann, Elisabeth G E de Vries, Marcel A T M van Vugt.
Front Genet, 2015 Apr 09; 6. PMID: 25852742    Free PMC article.
Review.
Therapies for triple negative breast cancer.
Eleni Andreopoulou, Sarah J Schweber, Joseph A Sparano, Hayley M McDaid.
Expert Opin Pharmacother, 2015 Apr 18; 16(7). PMID: 25881743    Free PMC article.
Review.
A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Moria H Belanger, Lena Dolman, +5 authors, Patricia N Tonin.
J Ovarian Res, 2015 Apr 18; 8. PMID: 25884701    Free PMC article.
Exploiting replicative stress to treat cancer.
Matthias Dobbelstein, Claus Storgaard Sørensen.
Nat Rev Drug Discov, 2015 May 09; 14(6). PMID: 25953507
Highly Cited. Review.
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Gretchen Glaser, S John Weroha, +4 authors, Paul Haluska.
PLoS One, 2015 May 12; 10(5). PMID: 25962155    Free PMC article.
Single cell resolution in vivo imaging of DNA damage following PARP inhibition.
Katherine S Yang, Rainer H Kohler, +2 authors, Ralph Weissleder.
Sci Rep, 2015 May 20; 5. PMID: 25984718    Free PMC article.
Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Guoyan Liu, Da Yang, +17 authors, Wei Zhang.
J Natl Cancer Inst, 2015 May 23; 107(7). PMID: 25995442    Free PMC article.
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Tesa M Severson, Justine Peeters, +16 authors, Sabine Linn.
Mol Oncol, 2015 May 26; 9(8). PMID: 26004083    Free PMC article.
Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Yuriko Uehara, Katsutoshi Oda, +20 authors, Hiroyuki Aburatani.
PLoS One, 2015 Jun 05; 10(6). PMID: 26043110    Free PMC article.
Deciphering the BRCA1 Tumor Suppressor Network.
Qinqin Jiang, Roger A Greenberg.
J Biol Chem, 2015 Jun 07; 290(29). PMID: 26048987    Free PMC article.
Review.
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer.
Jung-Min Lee, Jane B Trepel, +12 authors, Elise C Kohn.
Front Oncol, 2015 Jun 18; 5. PMID: 26082895    Free PMC article.
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Hongying Sui, Caixia Shi, Zhipeng Yan, Hucheng Li.
Drug Des Devel Ther, 2015 Jul 01; 9. PMID: 26124641    Free PMC article.
PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
Mohamed A Ghonim, Kusma Pyakurel, +12 authors, A Hamid Boulares.
J Transl Med, 2015 Jul 15; 13. PMID: 26169874    Free PMC article.
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
Ruud van der Noll, Serena Marchetti, +6 authors, Jan H M Schellens.
Br J Cancer, 2015 Jul 17; 113(3). PMID: 26180927    Free PMC article.
Profile of veliparib and its potential in the treatment of solid tumors.
Lars M Wagner.
Onco Targets Ther, 2015 Aug 08; 8. PMID: 26251615    Free PMC article.
Review.
PARP inhibitors in the management of breast cancer: current data and future prospects.
Luca Livraghi, Judy E Garber.
BMC Med, 2015 Aug 14; 13. PMID: 26268938    Free PMC article.
Highly Cited. Review.
Olaparib in the management of ovarian cancer.
Kristin Bixel, John L Hays.
Pharmgenomics Pers Med, 2015 Aug 27; 8. PMID: 26309417    Free PMC article.
Review.
Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
See-Hyoung Park, Sang Jae Noh, +9 authors, Kyu Yun Jang.
Transl Oncol, 2015 Aug 28; 8(4). PMID: 26310369    Free PMC article.
Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.
Maud Marques, Marie-Claude Beauchamp, +7 authors, Michael Witcher.
BMC Med, 2015 Sep 12; 13. PMID: 26354718    Free PMC article.
Nivolumab and Olaparib.
Dominic A Solimando, J Aubrey Waddell.
Hosp Pharm, 2015 Sep 26; 50(5). PMID: 26405320    Free PMC article.
Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome.
E Hedström, C Pederiva, +4 authors, M Farnebo.
Cell Death Dis, 2015 Oct 02; 6. PMID: 26426684    Free PMC article.
Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.
Geraldine OʼSullivan Coyne, Alice Chen, Shivaani Kummar.
Curr Opin Oncol, 2015 Oct 09; 27(6). PMID: 26447876    Free PMC article.
Review.
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea.
Cancer Discov, 2015 Oct 16; 5(11). PMID: 26463832    Free PMC article.
Highly Cited. Review.
Targeted Therapies in Triple-Negative Breast Cancer.
Frederik Marmé, Andreas Schneeweiss.
Breast Care (Basel), 2015 Nov 12; 10(3). PMID: 26557820    Free PMC article.
Review.
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.
Denis Velic, Anthony M Couturier, +4 authors, Jean-Yves Masson.
Biomolecules, 2015 Nov 28; 5(4). PMID: 26610585    Free PMC article.
Review.
Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.
Hubert Fleury, Laudine Communal, +6 authors, Anne-Marie Mes-Masson.
Genes Cancer, 2015 Dec 02; 6(9-10). PMID: 26622941    Free PMC article.
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
Jonathan A Ledermann, Fatima El-Khouly.
Br J Cancer, 2015 Dec 17; 113 Suppl 1. PMID: 26669450    Free PMC article.
Review.
The development of PARP inhibitors in ovarian cancer: from bench to bedside.
Yvette Drew.
Br J Cancer, 2015 Dec 17; 113 Suppl 1. PMID: 26669452    Free PMC article.
Review.
The fate of chemoresistance in triple negative breast cancer (TNBC).
Elma A O'Reilly, Luke Gubbins, +8 authors, Amanda McCann.
BBA Clin, 2015 Dec 18; 3. PMID: 26676166    Free PMC article.
Highly Cited. Review.
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Susan M Domchek, Carol Aghajanian, +13 authors, Bella Kaufman.
Gynecol Oncol, 2016 Jan 03; 140(2). PMID: 26723501    Free PMC article.
Highly Cited.
Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.
Annabeth Høgh Petersen, Mads Malik Aagaard, +3 authors, Anders Bojesen.
Eur J Hum Genet, 2016 Jan 07; 24(8). PMID: 26733283    Free PMC article.
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Katherine M Bell-McGuinn, Jason A Konner, +6 authors, Carol Aghajanian.
Int J Gynecol Cancer, 2016 Jan 09; 26(2). PMID: 26745694    Free PMC article.
BRCAness revisited.
Christopher J Lord, Alan Ashworth.
Nat Rev Cancer, 2016 Jan 19; 16(2). PMID: 26775620
Highly Cited. Review.
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Yi Du, Hirohito Yamaguchi, +22 authors, Mien-Chie Hung.
Nat Med, 2016 Jan 19; 22(2). PMID: 26779812    Free PMC article.
Highly Cited.
[Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wei Wang, Bixia Duan, Li Zeng.
Zhongguo Fei Ai Za Zhi, 2016 Jan 26; 19(1). PMID: 26805733    Free PMC article.
DNA repair targeted therapy: The past or future of cancer treatment?
Navnath S Gavande, Pamela S VanderVere-Carozza, +4 authors, John J Turchi.
Pharmacol Ther, 2016 Feb 21; 160. PMID: 26896565    Free PMC article.
Highly Cited. Review.
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
J Sehouli, E I Braicu, R Chekerov.
Geburtshilfe Frauenheilkd, 2016 Mar 05; 76(2). PMID: 26941449    Free PMC article.
Review.
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Joyce F Liu, Ursula A Matulonis.
Curr Oncol Rep, 2016 Mar 18; 18(5). PMID: 26984416
Review.
Role of Biomarkers in the Development of PARP Inhibitors.
Bratati Ganguly, Sonia C Dolfi, +2 authors, Kim M Hirshfield.
Biomark Cancer, 2016 Mar 22; 8(Suppl 1). PMID: 26997874    Free PMC article.
Review.
Emerging therapeutic targets in metastatic progression: A focus on breast cancer.
Zhuo Li, Yibin Kang.
Pharmacol Ther, 2016 Mar 24; 161. PMID: 27000769    Free PMC article.
Review.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Yvette Drew, Jonathan Ledermann, +14 authors, Ruth Plummer.
Br J Cancer, 2016 Mar 24; 114(7). PMID: 27002934    Free PMC article.
Highly Cited.
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
Joyce Liu, Shannon N Westin.
Gynecol Oncol, 2016 Mar 27; 141(1). PMID: 27016231    Free PMC article.
Review.
PARP inhibitors: the race is on.
Jessica S Brown, Stan B Kaye, Timothy A Yap.
Br J Cancer, 2016 Mar 31; 114(7). PMID: 27022824    Free PMC article.
Highly Cited.
Comparative genomic analysis of primary tumors and metastases in breast cancer.
François Bertucci, Pascal Finetti, +9 authors, Max Chaffanet.
Oncotarget, 2016 Mar 31; 7(19). PMID: 27028851    Free PMC article.
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.
E Clair McClung, Robert M Wenham.
Int J Womens Health, 2016 Apr 07; 8. PMID: 27051317    Free PMC article.
Review.
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
Christine E Edmonds, Mehran Makvandi, +8 authors, Robert H Mach.
Am J Nucl Med Mol Imaging, 2016 Apr 14; 6(1). PMID: 27069769    Free PMC article.
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
Eric X Chen, Derek J Jonker, +5 authors, Lesley Seymour.
Invest New Drugs, 2016 Apr 15; 34(4). PMID: 27075016
Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
S B Kaye.
Ann Oncol, 2016 May 04; 27 Suppl 1. PMID: 27141062    Free PMC article.
Review.
PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2.
Nan Li, Lin Feng, +6 authors, Junjie Chen.
Cell Rep, 2016 May 07; 15(4). PMID: 27149849    Free PMC article.
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
J Mateo, V Moreno, +15 authors, L R Molife.
Target Oncol, 2016 May 14; 11(3). PMID: 27169564
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2016 Oct 19; 13(11). PMID: 27184417    Free PMC article.
Highly Cited. Review.
Profile of olaparib in the treatment of advanced ovarian cancer.
Dana M Chase, Shreya Patel, Kristin Shields.
Int J Womens Health, 2016 May 18; 8. PMID: 27186080    Free PMC article.
Review.
Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients.
Brett Marinelli, Carina Espinet-Col, +4 authors, Wolfgang A Weber.
Am J Nucl Med Mol Imaging, 2016 May 18; 6(2). PMID: 27186439    Free PMC article.
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Yifan Wang, Andrea J Bernhardy, +36 authors, Neil Johnson.
Cancer Res, 2016 May 20; 76(9). PMID: 27197267    Free PMC article.
Highly Cited.
Targeted therapy in ovarian cancer.
Hui Jun Lim, William Ledger.
Womens Health (Lond), 2016 May 25; 12(3). PMID: 27215391    Free PMC article.
Review.
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Kathleen N Moore, Bradley J Monk.
Oncologist, 2016 Jun 04; 21(8). PMID: 27256873    Free PMC article.
Review.
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.
Mehran Makvandi, Kuiying Xu, +8 authors, Robert H Mach.
Cancer Res, 2016 Jun 05; 76(15). PMID: 27261505    Free PMC article.
Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.
See-Hyoung Park, Young Min Chung, +3 authors, Mickey C-T Hu.
Oncotarget, 2016 Jun 11; 7(27). PMID: 27283899    Free PMC article.
Triple-negative breast cancer: treatment challenges and solutions.
Joëlle Collignon, Laurence Lousberg, Hélène Schroeder, Guy Jerusalem.
Breast Cancer (Dove Med Press), 2016 Jun 11; 8. PMID: 27284266    Free PMC article.
Highly Cited.
Trial watch - inhibiting PARP enzymes for anticancer therapy.
Antonella Sistigu, Gwenola Manic, Florine Obrist, Ilio Vitale.
Mol Cell Oncol, 2016 Jun 17; 3(2). PMID: 27308587    Free PMC article.
Review.
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Philip C Schouten, Gwen M H E Dackus, +4 authors, Sabine C Linn.
Trials, 2016 Jun 22; 17(1). PMID: 27323902    Free PMC article.
Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.
Chong Hyun Suh, Sree H Tirumani, +3 authors, Atul B Shinagare.
Br J Radiol, 2016 Jun 23; 89(1066). PMID: 27331884    Free PMC article.
Review.
Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
Hubert Fleury, Euridice Carmona, +5 authors, Anne-Marie Mes-Masson.
Oncotarget, 2016 Jul 05; 8(25). PMID: 27374179    Free PMC article.
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Kan Yonemori, Kenji Tamura, +9 authors, Yasuo Takahashi.
Cancer Chemother Pharmacol, 2016 Jul 17; 78(3). PMID: 27422301    Free PMC article.
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Dong Wang, Chengbo Li, +8 authors, Pixu Liu.
Gynecol Oncol, 2016 Jul 19; 142(3). PMID: 27426307    Free PMC article.
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Rinske Drost, Kiranjit K Dhillon, +26 authors, Jos Jonkers.
J Clin Invest, 2016 Jul 28; 126(8). PMID: 27454287    Free PMC article.
Targeting DNA Replication Stress for Cancer Therapy.
Jun Zhang, Qun Dai, Dongkyoo Park, Xingming Deng.
Genes (Basel), 2016 Aug 23; 7(8). PMID: 27548226    Free PMC article.
Review.
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Ruoxi Hong, Fei Ma, +6 authors, Binghe Xu.
BMC Cancer, 2016 Sep 11; 16(1). PMID: 27613518    Free PMC article.
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Mariam M AlHilli, Marc A Becker, +15 authors, Paul Haluska.
Gynecol Oncol, 2016 Oct 25; 143(2). PMID: 27614696    Free PMC article.
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Anselmo Papa, Davide Caruso, +2 authors, Federica Tomao.
J Transl Med, 2016 Sep 17; 14. PMID: 27634150    Free PMC article.
Review.
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.
Stephen Murata, Catherine Zhang, +3 authors, Eun-Kyoung Breuer.
Biomed Res Int, 2016 Sep 20; 2016. PMID: 27642590    Free PMC article.
Review.
Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Kyoung Min Kim, Young Jae Moon, +9 authors, Kyu Yun Jang.
PLoS One, 2016 Sep 20; 11(9). PMID: 27643881    Free PMC article.
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
Jung-Min Lee, Cody J Peer, +13 authors, Elise C Kohn.
Clin Cancer Res, 2016 Sep 25; 23(6). PMID: 27663600    Free PMC article.
Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Minsu Kwon, Hyejin Jang, Eun Hye Kim, Jong-Lyel Roh.
Cell Cycle, 2016 Oct 18; 15(22). PMID: 27686740    Free PMC article.
Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data.
Fan Zhang, Chunyan Ren, +6 authors, Martin J Walsh.
Oncotarget, 2016 Oct 01; 7(44). PMID: 27690302    Free PMC article.
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Junko Murai, Ying Feng, +4 authors, Yves Pommier.
Oncotarget, 2016 Oct 07; 7(47). PMID: 27708213    Free PMC article.
Highly Cited.
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
G E Konecny, R S Kristeleit.
Br J Cancer, 2016 Oct 14; 115(10). PMID: 27736844    Free PMC article.
Highly Cited. Review.
Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
Tereza Vaclová, Nicholas T Woods, +10 authors, Ana Osorio.
Hum Mol Genet, 2016 Oct 16; 25(24). PMID: 27742776    Free PMC article.
Triple-negative breast cancer: is there a treatment on the horizon?
Hui Yao, Guangchun He, +4 authors, Xiyun Deng.
Oncotarget, 2016 Oct 22; 8(1). PMID: 27765921    Free PMC article.
Highly Cited. Review.
Novel therapeutic strategies for patients with triple-negative breast cancer.
Jun-Fei Zhang, Jia Liu, Yu Wang, Bin Zhang.
Onco Targets Ther, 2016 Nov 02; 9. PMID: 27799799    Free PMC article.
Review.
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
Jonathan A Ledermann, Philipp Harter, +14 authors, Ursula Matulonis.
Br J Cancer, 2016 Nov 09; 115(11). PMID: 27824811    Free PMC article.
The rise of genomic profiling in ovarian cancer.
Rebecca A Previs, Anil K Sood, Gordon B Mills, Shannon N Westin.
Expert Rev Mol Diagn, 2016 Nov 10; 16(12). PMID: 27828713    Free PMC article.
Review.
PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Loren S Michel, Samantha Dyroff, +12 authors, Delphine L Chen.
Radiology, 2016 Nov 15; 282(2). PMID: 27841728    Free PMC article.
Recent developments and translational aspects in targeted therapy for metastatic breast cancer.
Maximilian Marhold, Rupert Bartsch, Christoph Zielinski.
ESMO Open, 2016 Nov 16; 1(3). PMID: 27843605    Free PMC article.
Review.
Sex differences in stroke therapies.
Farida Sohrabji, Min Jung Park, Amanda H Mahnke.
J Neurosci Res, 2016 Nov 22; 95(1-2). PMID: 27870437    Free PMC article.
Review.
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Aniello Cerrato, Francesco Morra, Angela Celetti.
J Exp Clin Cancer Res, 2016 Nov 26; 35(1). PMID: 27884198    Free PMC article.
Review.
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Tingting Jiang, Weiwei Shi, +8 authors, Christos Hatzis.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959926    Free PMC article.
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
U A Matulonis, G M Wulf, +20 authors, E Winer.
Ann Oncol, 2016 Dec 21; 28(3). PMID: 27993796    Free PMC article.
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
M K Wilson, E Pujade-Lauraine, +21 authors, participants of the Fifth Ovarian Cancer Consensus Conference.
Ann Oncol, 2016 Dec 21; 28(4). PMID: 27993805    Free PMC article.
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models.
Hyoung Kim, Erin George, +7 authors, Fiona Simpkins.
Clin Cancer Res, 2016 Dec 21; 23(12). PMID: 27993965    Free PMC article.
Highly Cited.
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Jiayan Luo, Juan Jin, +5 authors, Xiaoxiang Guan.
Int J Biol Sci, 2016 Dec 21; 12(12). PMID: 27994514    Free PMC article.
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Paul M Wilkerson, Konstantin J Dedes, +10 authors, Jorge S Reis-Filho.
Oncotarget, 2016 Dec 22; 8(4). PMID: 28002809    Free PMC article.
Chemoresistance and targeted therapies in ovarian and endometrial cancers.
Kevin Brasseur, Nicolas Gévry, Eric Asselin.
Oncotarget, 2016 Dec 23; 8(3). PMID: 28008141    Free PMC article.
Review.
Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.
Yuan Xie, Yan Jiang, +9 authors, Hai-Tao Zhao.
World J Gastroenterol, 2016 Dec 29; 22(46). PMID: 28028375    Free PMC article.
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
Lorena Incorvaia, Francesc Passiglia, +9 authors, Antonio Russo.
Oncotarget, 2017 Jan 06; 8(14). PMID: 28055979    Free PMC article.
Review.
Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario.
Jacob McGee, Karen Panabaker, +3 authors, Salimah Z Shariff.
Int J Gynecol Cancer, 2017 Jan 11; 27(3). PMID: 28072594    Free PMC article.
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
Geraldine O'Sullivan Coyne, Alice P Chen, Robert Meehan, James H Doroshow.
Drugs, 2017 Jan 13; 77(2). PMID: 28078645    Free PMC article.
Review.
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.
Alberto Ocana, Atanasio Pandiella.
Oncotarget, 2017 Jan 22; 8(13). PMID: 28108739    Free PMC article.
Review.
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
Kim A Reiss, Joseph M Herman, +16 authors, Nilofer S Azad.
Gynecol Oncol, 2017 Jan 23; 144(3). PMID: 28109627    Free PMC article.
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Marise R Heerma van Voss, Justin D Brilliant, +4 authors, Venu Raman.
Med Oncol, 2017 Feb 01; 34(3). PMID: 28138868    Free PMC article.
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Wei Song, Lin Tang, +5 authors, Xiaoxiang Guan.
Sci Rep, 2017 Feb 09; 7. PMID: 28176879    Free PMC article.
Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
Melissa K Frey, Bhavana Pothuri.
Gynecol Oncol Res Pract, 2017 Mar 03; 4. PMID: 28250960    Free PMC article.
Review.
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Michael J Pishvaian, Andrew V Biankin, +4 authors, Jonathan R Brody.
Br J Cancer, 2017 Mar 16; 116(8). PMID: 28291774    Free PMC article.
PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth.
Science, 2017 Mar 18; 355(6330). PMID: 28302823    Free PMC article.
Highly Cited. Review.
Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells.
Joseph T Decker, Eric C Hobson, +5 authors, Lonnie D Shea.
Biotechnol Bioeng, 2017 Mar 23; 114(9). PMID: 28322442    Free PMC article.
Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.
Takuhei Yokoyama, Elise C Kohn, Ethan Brill, Jung-Min Lee.
Int J Oncol, 2017 Mar 30; 50(4). PMID: 28350129    Free PMC article.
Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens.
Eleni G Christodoulou, Hai Yang, +3 authors, Michael Schroeder.
Oncotarget, 2017 Apr 19; 8(21). PMID: 28415695    Free PMC article.
Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors.
Anna Mária Cseh, Zsolt Fábián, Balázs Sümegi, Luca Scorrano.
Oncotarget, 2017 Apr 22; 8(30). PMID: 28430591    Free PMC article.
Review.
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Saeed Rafii, Charlie Gourley, +14 authors, Timothy A Yap.
Oncotarget, 2017 Apr 30; 8(29). PMID: 28454085    Free PMC article.
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Moito Iijima, Kouji Banno, +11 authors, Daisuke Aoki.
Oncol Lett, 2017 Apr 30; 13(3). PMID: 28454214    Free PMC article.
Emerging therapies for breast cancer.
Xichun Hu, Wei Huang, Minhao Fan.
J Hematol Oncol, 2017 Apr 30; 10(1). PMID: 28454587    Free PMC article.
Review.
Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.
Amanda Parkes, Banu K Arun, Jennifer K Litton.
Oncologist, 2017 May 05; 22(6). PMID: 28469042    Free PMC article.
Review.
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
Tarra Evans, Ursula Matulonis.
Ther Adv Med Oncol, 2017 May 12; 9(4). PMID: 28491146    Free PMC article.
Review.
Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.
Anne L van de Ven, Shifalika Tangutoori, +8 authors, Srinivas Sridhar.
Mol Cancer Ther, 2017 May 14; 16(7). PMID: 28500233    Free PMC article.
PARP Inhibitors in Prostate Cancer.
Praveen Ramakrishnan Geethakumari, Matthew J Schiewer, Karen E Knudsen, Wm Kevin Kelly.
Curr Treat Options Oncol, 2017 May 26; 18(6). PMID: 28540598
Review.
Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.
Hannah Shipman, Samantha Flynn, +5 authors, Nicholas J Hulbert-Williams.
J Genet Couns, 2017 May 26; 26(6). PMID: 28540621
Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Qianying Zhao, Jiaxin Yang, +4 authors, BGI Group.
J Gynecol Oncol, 2017 May 26; 28(4). PMID: 28541631    Free PMC article.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Tessa G Steenbruggen, Mette S van Ramshorst, +3 authors, Gabe S Sonke.
Drugs, 2017 Jun 16; 77(12). PMID: 28616845
Review.
Synthetic lethality and cancer.
Nigel J O'Neil, Melanie L Bailey, Philip Hieter.
Nat Rev Genet, 2017 Jun 27; 18(10). PMID: 28649135
Highly Cited. Review.
Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.
Ying Zeng, Agnieszka A Rucki, Xu Che, Lei Zheng.
J Gastrointest Oncol, 2017 Jul 25; 8(3). PMID: 28736631    Free PMC article.
Review.
FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.
Kathryn M Buchtel, Kristen J Vogel Postula, +3 authors, Scott M Weissman.
J Genet Couns, 2017 Aug 07; 27(1). PMID: 28780754
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
S Mazzucchelli, M Truffi, +9 authors, F Corsi.
Sci Rep, 2017 Aug 10; 7(1). PMID: 28790402    Free PMC article.
BRCA mutation in ovarian cancer: testing, implications and treatment considerations.
Robert T Neff, Leigha Senter, Ritu Salani.
Ther Adv Med Oncol, 2017 Aug 11; 9(8). PMID: 28794804    Free PMC article.
Review.
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Zhor Senhaji Mouhri, Elliot Goodfellow, Bertrand Jean-Claude.
BMC Cancer, 2017 Aug 13; 17(1). PMID: 28800752    Free PMC article.
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.
Joline S J Lim, David S P Tan.
Cancers (Basel), 2017 Aug 23; 9(8). PMID: 28829366    Free PMC article.
Review.
Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future.
Emma C Fields, William P McGuire, Lilie Lin, Sarah M Temkin.
Front Oncol, 2017 Sep 06; 7. PMID: 28871275    Free PMC article.
Review.
BRCA1 gene: function and deficiency.
Miho Takaoka, Yoshio Miki.
Int J Clin Oncol, 2017 Sep 09; 23(1). PMID: 28884397
Review.
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Charles-André Philip, Ido Laskov, +8 authors, Amber Yasmeen.
BMC Cancer, 2017 Sep 10; 17(1). PMID: 28886696    Free PMC article.
Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Thomas J Herzog, Bradley J Monk.
Gynecol Oncol Res Pract, 2017 Sep 15; 4. PMID: 28904804    Free PMC article.
Review.
Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
Ana C Gregório, Manuela Lacerda, +3 authors, João Nuno Moreira.
Pathol Oncol Res, 2017 Sep 16; 24(4). PMID: 28913723
Review.
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
Denise M Wolf, Christina Yau, +18 authors, Laura van 't Veer.
NPJ Breast Cancer, 2017 Sep 28; 3. PMID: 28948212    Free PMC article.
Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.
Jolien S de Groot, Paul J van Diest, +10 authors, Patrick W B Derksen.
Oncotarget, 2017 Oct 06; 8(37). PMID: 28977823    Free PMC article.
How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.
Diana P Saraiva, M Guadalupe Cabral, António Jacinto, Sofia Braga.
ESMO Open, 2017 Oct 12; 2(4). PMID: 29018573    Free PMC article.
Review.
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Jung-Min Lee, John L Hays, +13 authors, Elise C Kohn.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108297    Free PMC article.
Current status of poly(ADP-ribose) polymerase inhibitors and future directions.
Akihiro Ohmoto, Shinichi Yachida.
Onco Targets Ther, 2017 Nov 16; 10. PMID: 29138572    Free PMC article.
Highly Cited. Review.
Hesperidin inhibits ovarian cancer cell viability through endoplasmic reticulum stress signaling pathways.
Jun Zhao, Yali Li, Jinfang Gao, Yinshan De.
Oncol Lett, 2017 Nov 17; 14(5). PMID: 29142606    Free PMC article.
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Atsushi Osoegawa, Joell J Gills, Shigeru Kawabata, Phillip A Dennis.
Oncotarget, 2017 Nov 21; 8(50). PMID: 29152062    Free PMC article.
Management of hereditary breast and ovarian cancer.
Hideko Yamauchi, Junko Takei.
Int J Clin Oncol, 2017 Dec 01; 23(1). PMID: 29185095
Review.
Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15.
Rachel M McQuade, Vanesa Stojanovska, +6 authors, Kulmira Nurgali.
Br J Pharmacol, 2017 Dec 02; 175(4). PMID: 29194564    Free PMC article.
BRCA mutations in the manifestation and treatment of ovarian cancer.
Zimin Pan, Xing Xie.
Oncotarget, 2017 Dec 13; 8(57). PMID: 29228641    Free PMC article.
Review.
EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
Raymond W-M Lung, Pok-Man Hau, +16 authors, Kwok-Wai Lo.
J Pathol, 2017 Dec 13; 244(4). PMID: 29230817    Free PMC article.
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.
J K Litton, M Scoggins, +14 authors, B K Arun.
NPJ Breast Cancer, 2017 Dec 15; 3. PMID: 29238749    Free PMC article.
Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
Liang Song, Ewan M McNeil, +3 authors, David W Melton.
BMC Cancer, 2017 Dec 20; 17(1). PMID: 29254481    Free PMC article.
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Maurie Markman.
Womens Health (Lond), 2018 Jan 10; 14. PMID: 29313444    Free PMC article.
Review.
Precision oncology in the age of integrative genomics.
Chandan Kumar-Sinha, Arul M Chinnaiyan.
Nat Biotechnol, 2018 Jan 11; 36(1). PMID: 29319699    Free PMC article.
Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.
Ethan Brill, Takuhei Yokoyama, +3 authors, Jung-Min Lee.
Oncotarget, 2018 Jan 18; 8(67). PMID: 29340034    Free PMC article.
Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.
Haitao Yang, MariaLynn Jaeger, +3 authors, Tao Weitao.
J Cancer, 2018 Jan 19; 9(2). PMID: 29344267    Free PMC article.
Review.
Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.
Haolong Li, Lei Liu, +2 authors, Da Xing.
Cell Death Dis, 2018 Jan 28; 9(2). PMID: 29374168    Free PMC article.
Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents.
Catherine Terret, Chiara Russo.
Drugs Aging, 2018 Feb 02; 35(2). PMID: 29388072
Review.
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.
Claudia Omarini, Giorgia Guaitoli, +4 authors, Federico Piacentini.
Cancer Manag Res, 2018 Feb 03; 10. PMID: 29391830    Free PMC article.
Review.
Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
Lucia Guidugli, Hermela Shimelis, +10 authors, Fergus J Couch.
Am J Hum Genet, 2018 Feb 06; 102(2). PMID: 29394989    Free PMC article.
Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population.
Min Fang, Li Zhu, +6 authors, Yue Yu.
Oncol Lett, 2018 Feb 13; 15(3). PMID: 29435039    Free PMC article.
New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Giovanni Blandino, Silvia Di Agostino.
J Exp Clin Cancer Res, 2018 Feb 17; 37(1). PMID: 29448954    Free PMC article.
Highly Cited. Review.
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Robert D Morgan, Andrew R Clamp, +2 authors, Gordon C Jayson.
Cancer Chemother Pharmacol, 2018 Feb 22; 81(4). PMID: 29464354    Free PMC article.
Review.
PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Yize Mao, Xin Huang, +5 authors, Shengping Li.
Cancer Med, 2018 Feb 27; 7(4). PMID: 29479816    Free PMC article.
PARP inhibitors for homologous recombination-deficient prostate cancer.
Eric S Christenson, Emmanuel S Antonarakis.
Expert Opin Emerg Drugs, 2018 Mar 30; 23(2). PMID: 29595348    Free PMC article.
Review.
Update on PARP Inhibitors in Breast Cancer.
Alexandra S Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung-Min Lee.
Curr Treat Options Oncol, 2018 Apr 13; 19(5). PMID: 29644491    Free PMC article.
Review.
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Anita A Turk, Kari B Wisinski.
Cancer, 2018 Apr 17; 124(12). PMID: 29660759    Free PMC article.
Review.
Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
Domenica Lorusso, Elisa Tripodi, +4 authors, Francesco Raspagliesi.
Drug Des Devel Ther, 2018 Jun 09; 12. PMID: 29881257    Free PMC article.
Review.
Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Narjust Duma, Kelly C Gast, +2 authors, Ciara C O'Sullivan.
Curr Oncol Rep, 2018 Jun 10; 20(8). PMID: 29884921
Review.
Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies.
Evelyn M Brosnan, Carey K Anders.
Ann Transl Med, 2018 Jun 19; 6(9). PMID: 29911111    Free PMC article.
Review.
Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.
John Paul Shen, Trey Ideker.
J Mol Biol, 2018 Jun 23; 430(18 Pt A). PMID: 29932943    Free PMC article.
Review.
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.
Graziela Z Dal Molin, Kohei Omatsu, Anil K Sood, Robert L Coleman.
Ther Adv Med Oncol, 2018 Jul 07; 10. PMID: 29977351    Free PMC article.
Review.
Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine.
Jesus Rolando Delgado-Balderas, Maria Lourdes Garza-Rodriguez, +9 authors, Hugo A Barrera-Saldaña.
Genes (Basel), 2018 Jul 13; 9(7). PMID: 29997359    Free PMC article.
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Anna Minchom, Caterina Aversa, Juanita Lopez.
Ther Adv Med Oncol, 2018 Jul 20; 10. PMID: 30023007    Free PMC article.
Review.
Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.
Ena Arora, Muhammad Masab, +3 authors, Gabor Varadi.
Cureus, 2018 Jul 28; 10(5). PMID: 30050740    Free PMC article.
Review.
Copy number signatures and mutational processes in ovarian carcinoma.
Geoff Macintyre, Teodora E Goranova, +36 authors, James D Brenton.
Nat Genet, 2018 Aug 15; 50(9). PMID: 30104763    Free PMC article.
Highly Cited.
Advances in the use of PARP inhibitor therapy for breast cancer.
Kelly E McCann, Sara A Hurvitz.
Drugs Context, 2018 Aug 18; 7. PMID: 30116283    Free PMC article.
Review.
Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Yongping Liu, Jun Meng, Guichan Wang.
Drug Des Devel Ther, 2018 Oct 03; 12. PMID: 30271116    Free PMC article.
Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.
Margarita Romeo, Juan Carlos Pardo, +6 authors, Ricard Mesía.
Int J Mol Sci, 2018 Oct 24; 19(10). PMID: 30347758    Free PMC article.
Review.
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Marta Castroviejo-Bermejo, Cristina Cruz, +36 authors, Violeta Serra.
EMBO Mol Med, 2018 Nov 01; 10(12). PMID: 30377213    Free PMC article.
Highly Cited.
PARP-1 regulates DNA repair factor availability.
Matthew J Schiewer, Amy C Mandigo, +29 authors, Karen E Knudsen.
EMBO Mol Med, 2018 Nov 24; 10(12). PMID: 30467127    Free PMC article.
EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.
Qiongzhu Dong, Yi Du, +9 authors, Mien-Chie Hung.
Cancer Res, 2018 Dec 24; 79(4). PMID: 30573522    Free PMC article.
Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.
Yoshiyuki Suehara, Deepu Alex, +15 authors, Marc Ladanyi.
Clin Cancer Res, 2019 Jun 09; 25(21). PMID: 31175097    Free PMC article.
A decade of clinical development of PARP inhibitors in perspective.
J Mateo, C J Lord, +7 authors, J S de Bono.
Ann Oncol, 2019 Jun 21; 30(9). PMID: 31218365    Free PMC article.
Highly Cited. Review.
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Anna R Michmerhuizen, Andrea M Pesch, +13 authors, Corey Speers.
Mol Cancer Ther, 2019 Aug 16; 18(11). PMID: 31413177    Free PMC article.
Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
Hitomi Yamashita, Kentaro Nakayama, +11 authors, Satoru Kyo.
Int J Mol Sci, 2019 Oct 19; 20(20). PMID: 31623180    Free PMC article.
Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting.
Julian Biau, Emmanuel Chautard, Pierre Verrelle, Marie Dutreix.
Front Oncol, 2019 Oct 28; 9. PMID: 31649878    Free PMC article.
Review.
MacroH2A1 Regulation of Poly(ADP-Ribose) Synthesis and Stability Prevents Necrosis and Promotes DNA Repair.
Penelope D Ruiz, Gregory A Hamilton, Jong Woo Park, Matthew J Gamble.
Mol Cell Biol, 2019 Oct 23; 40(1). PMID: 31636161    Free PMC article.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, +29 authors, Michael A Bookman.
N Engl J Med, 2019 Sep 29; 381(25). PMID: 31562800    Free PMC article.
Highly Cited.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Michael Friedlander, Ursula Matulonis, +18 authors, Jonathan Ledermann.
Br J Cancer, 2018 Oct 26; 119(9). PMID: 30353045    Free PMC article.
An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome.
Vikas T Talreja, Vanita Noronha, +2 authors, Kumar Prabhash.
South Asian J Cancer, 2020 Jan 21; 9(1). PMID: 31956609    Free PMC article.
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
Rachel L Mintz, Yeh-Hsing Lao, +8 authors, Kam W Leong.
Bioeng Transl Med, 2020 Jan 29; 5(1). PMID: 31989039    Free PMC article.
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Chenggong Sun, Wenyu Cao, +8 authors, Beihua Kong.
J Hematol Oncol, 2020 Feb 02; 13(1). PMID: 32005272    Free PMC article.
Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma.
Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Alessandro D Santin.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016027    Free PMC article.
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam, Fang Fang, +10 authors, Kenneth P Nephew.
Clin Cancer Res, 2018 Apr 05; 24(13). PMID: 29615458    Free PMC article.
Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.
Lucy Gentles, Bojidar Goranov, +7 authors, Rachel L O'Donnell.
Cancers (Basel), 2019 Mar 16; 11(3). PMID: 30871186    Free PMC article.
Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Yolanda Jerez, Ivan Márquez-Rodas, +3 authors, Sara López-Tarruella.
Drugs, 2019 Dec 12; 80(2). PMID: 31823331
Review.
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
Nan Shao, Yawei Shi, +5 authors, Ying Lin.
Int J Biol Sci, 2019 Jun 12; 15(5). PMID: 31182917    Free PMC article.
Review.
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Panagiotis A Konstantinopoulos, William T Barry, +25 authors, Ursula A Matulonis.
Lancet Oncol, 2019 Mar 19; 20(4). PMID: 30880072    Free PMC article.
Highly Cited.
Epithelial ovarian cancer risk: A review of the current genetic landscape.
Nicola Flaum, Emma J Crosbie, +2 authors, Dafydd G Evans.
Clin Genet, 2019 May 18; 97(1). PMID: 31099061    Free PMC article.
Review.
PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Michelle Lightfoot, Lauren Montemorano, Kristin Bixel.
Curr Oncol Rep, 2020 Feb 19; 22(3). PMID: 32067102
Review.
Combination of PARP inhibitor and temozolomide to suppress chordoma progression.
Xiaoyu Cao, Yanxin Lu, +10 authors, Chunzhang Yang.
J Mol Med (Berl), 2019 Jun 16; 97(8). PMID: 31201471    Free PMC article.
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
Angela George, Stan Kaye, Susana Banerjee.
Nat Rev Clin Oncol, 2016 Dec 14; 14(5). PMID: 27958297
Review.
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Sarah J Hill, Brennan Decker, +19 authors, Alan D D'Andrea.
Cancer Discov, 2018 Sep 15; 8(11). PMID: 30213835    Free PMC article.
Highly Cited.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Darren R Hodgson, Brian A Dougherty, +16 authors, J Carl Barrett.
Br J Cancer, 2018 Oct 26; 119(11). PMID: 30353044    Free PMC article.
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Jianfeng Shen, Wei Zhao, +6 authors, Guang Peng.
Cancer Res, 2018 Nov 30; 79(2). PMID: 30482774    Free PMC article.
Highly Cited.
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
Chee Khoon Lee, Clare Scott, +11 authors, Michael Friedlander.
Br J Cancer, 2019 Jan 19; 120(3). PMID: 30655615    Free PMC article.
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Rachel M Hurley, Andrea E Wahner Hendrickson, +19 authors, Scott H Kaufmann.
Gynecol Oncol, 2019 Jan 29; 153(1). PMID: 30686551    Free PMC article.
Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Kaishun Hu, Wenjing Wu, +12 authors, Dong Yin.
EMBO Rep, 2019 Apr 04; 20(5). PMID: 30940648    Free PMC article.
Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
Erika J Lampert, John L Hays, +9 authors, Jung-Min Lee.
Oncotarget, 2019 May 14; 10(30). PMID: 31080557    Free PMC article.
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
Junko Murai, Anish Thomas, Markku Miettinen, Yves Pommier.
Pharmacol Ther, 2019 May 28; 201. PMID: 31128155    Free PMC article.
Highly Cited. Review.
BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
Nathan D Seligson, Esko A Kautto, +6 authors, James L Chen.
Oncologist, 2018 Dec 14; 24(7). PMID: 30541756    Free PMC article.
The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival.
T Jubin, A Kadam, +5 authors, R Begum.
Cell Prolif, 2016 Jun 23; 49(4). PMID: 27329285    Free PMC article.
Review.
PARP and PARG inhibitors in cancer treatment.
Dea Slade.
Genes Dev, 2020 Feb 08; 34(5-6). PMID: 32029455    Free PMC article.
Review.
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Kyung Jin Eoh, Hye Min Kim, +4 authors, Eun Ji Nam.
BMC Cancer, 2020 Mar 14; 20(1). PMID: 32164585    Free PMC article.
Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Rashid Gabbasov, I Daniel Benrubi, +4 authors, Denise C Connolly.
Cancer Biol Ther, 2019 Apr 02; 20(7). PMID: 30929564    Free PMC article.
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Xuan Jiang, Xiaoying Li, +2 authors, Zhenyu Zhang.
J Cell Mol Med, 2019 Jan 24; 23(4). PMID: 30672100    Free PMC article.
Review.
RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination.
Robert A Baldock, Catherine A Pressimone, +12 authors, Kara A Bernstein.
DNA Repair (Amst), 2019 Mar 06; 76. PMID: 30836272    Free PMC article.
Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer.
Yann Kieffer, Claire Bonneau, +3 authors, Fatima Mechta-Grigoriou.
Front Genet, 2020 Apr 08; 11. PMID: 32256521    Free PMC article.
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Richard T Penson, Ricardo Villalobos Valencia, +13 authors, Giovanni Scambia.
J Clin Oncol, 2020 Feb 20; 38(11). PMID: 32073956    Free PMC article.
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.
Nicola J Curtin.
Cancers (Basel), 2020 Mar 04; 12(3). PMID: 32121331    Free PMC article.
Review.
Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods.
Nuzhat Ahmed, Elif Kadife, +3 authors, George Kannourakis.
Cells, 2020 Mar 19; 9(3). PMID: 32183385    Free PMC article.
Review.
The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs.
Justin M Brown, Marie-Claire D Wasson, Paola Marcato.
Cells, 2020 Apr 05; 9(3). PMID: 32244924    Free PMC article.
Review.
Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
Min Chul Choi, Sohyun Hwang, +8 authors, Hee Jung An.
Cancer Res Treat, 2020 Feb 06; 52(2). PMID: 32019284    Free PMC article.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Alexandra S Zimmer, Erin Nichols, +13 authors, Jung-Min Lee.
J Immunother Cancer, 2019 Jul 28; 7(1). PMID: 31345267    Free PMC article.
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Stergios Boussios, Charlotte Abson, +6 authors, Nicholas Pavlidis.
Drugs R D, 2020 Mar 28; 20(2). PMID: 32215876    Free PMC article.
Review.
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
William Jacot, Evelyne Lopez-Crapez, +9 authors, Séverine Guiu.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235500    Free PMC article.
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.
Naveen Singh, S Louise Pay, +2 authors, Edward A Motea.
Cancers (Basel), 2020 Apr 17; 12(4). PMID: 32295316    Free PMC article.
Review.
Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
Semini Sumanasuriya, Johann De Bono.
Cold Spring Harb Perspect Med, 2017 Nov 05; 8(6). PMID: 29101113    Free PMC article.
Review.
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.
Tzu-Ting Huang, Erika J Lampert, Cynthia Coots, Jung-Min Lee.
Cancer Treat Rev, 2020 Apr 21; 86. PMID: 32311593    Free PMC article.
Review.
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Neha Chopra, Holly Tovey, +19 authors, Nicholas C Turner.
Nat Commun, 2020 May 31; 11(1). PMID: 32471999    Free PMC article.
Personalised cancer care: promises and challenges of targeted therapy.
Shi-Ming Tu, Mehmet A Bilen, Nizar M Tannir.
J R Soc Med, 2016 Mar 05; 109(3). PMID: 26933155    Free PMC article.
Ovarian cancer.
Ursula A Matulonis, Anil K Sood, +3 authors, Beth Y Karlan.
Nat Rev Dis Primers, 2016 Aug 26; 2. PMID: 27558151    Free PMC article.
Highly Cited. Review.
Exploring and comparing adverse events between PARP inhibitors.
Christopher J LaFargue, Graziela Z Dal Molin, Anil K Sood, Robert L Coleman.
Lancet Oncol, 2019 Jan 08; 20(1). PMID: 30614472    Free PMC article.
Highly Cited. Review.
Triple-negative breast cancer molecular subtyping and treatment progress.
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu.
Breast Cancer Res, 2020 Jun 11; 22(1). PMID: 32517735    Free PMC article.
Review.
PARP Inhibition in Cancer: An Update on Clinical Development.
Esha Sachdev, Roya Tabatabai, +2 authors, Monica M Mita.
Target Oncol, 2019 Oct 19; 14(6). PMID: 31625002
Review.
Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.
Xuan-Zhang Huang, Han Jia, +4 authors, Xin Zhou.
Front Oncol, 2020 Jul 03; 10. PMID: 32612955    Free PMC article.
Systematic Review.
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Yao Xiong, Yin Guo, +23 authors, Beibei Jiang.
Neoplasia, 2020 Jul 12; 22(9). PMID: 32652442    Free PMC article.
Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer.
Sandra Muñoz-Galván, Amancio Carnero.
Cells, 2020 Jun 10; 9(6). PMID: 32512891    Free PMC article.
Review.
The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
Ludivine Dion, Isis Carton, +8 authors, Vincent Lavoué.
J Clin Med, 2020 Jul 19; 9(7). PMID: 32679669    Free PMC article.
Review.
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Qiao Wang, Hongling Peng, +2 authors, Xia Zhao.
Signal Transduct Target Ther, 2020 Jul 31; 5(1). PMID: 32728057    Free PMC article.
Review.
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
Ainhoa Madariaga, Valerie Bowering, +2 authors, Stephanie Lheureux.
Int J Gynecol Cancer, 2020 Apr 12; 30(7). PMID: 32276934    Free PMC article.
Review.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Erika J Lampert, Alexandra Zimmer, +15 authors, Jung-Min Lee.
Clin Cancer Res, 2020 May 14; 26(16). PMID: 32398324    Free PMC article.
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.
Vera Loizzi, Girolamo Ranieri, +8 authors, Gennaro Cormio.
Oncol Lett, 2020 Aug 25; 20(4). PMID: 32831909    Free PMC article.
Review.
Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting.
Alice Bradbury, Rachel O'Donnell, +2 authors, Sweta Sharma Saha.
Cancers (Basel), 2020 Jul 28; 12(7). PMID: 32709004    Free PMC article.
Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
Wejdan M Alenezi, Caitlin T Fierheller, Neil Recio, Patricia N Tonin.
Genes (Basel), 2020 Jul 31; 11(8). PMID: 32726901    Free PMC article.
Review.
Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors.
Barbara Pasculli, Raffaela Barbano, +15 authors, Paola Parrella.
Front Oncol, 2020 Sep 10; 10. PMID: 32903519    Free PMC article.
Development of new medical treatment for epithelial ovarian cancer recurrence.
Rosanna Mancari, Giuseppe Cutillo, +7 authors, Enrico Vizza.
Gland Surg, 2020 Sep 22; 9(4). PMID: 32953630    Free PMC article.
Review.
Epigenetic based synthetic lethal strategies in human cancers.
Aiai Gao, Mingzhou Guo.
Biomark Res, 2020 Sep 26; 8. PMID: 32974031    Free PMC article.
Review.
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Isabella Faraoni, Grazia Graziani.
Cancers (Basel), 2018 Dec 07; 10(12). PMID: 30518089    Free PMC article.
Review.
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
Emanuel Nicolas, François Bertucci, Renaud Sabatier, Anthony Gonçalves.
Cancers (Basel), 2018 Dec 14; 10(12). PMID: 30544963    Free PMC article.
Review.
Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants.
Sumit Siddharth, Dipali Sharma.
Cancers (Basel), 2018 Dec 19; 10(12). PMID: 30558195    Free PMC article.
Review.
Translating the role of PARP inhibitors in triple-negative breast cancer.
Michèle Beniey, Takrima Haque, Saima Hassan.
Oncoscience, 2019 Feb 26; 6(1-2). PMID: 30800714    Free PMC article.
GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
J Alejandro Perez-Fidalgo, Maria Iglesias, +6 authors, Antonio Gonzalez-Martin.
Future Sci OA, 2019 Mar 02; 5(2). PMID: 30820349    Free PMC article.
Review.
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
Ainhoa Madariaga, Stephanie Lheureux, Amit M Oza.
Cancers (Basel), 2019 Mar 27; 11(3). PMID: 30909618    Free PMC article.
Review.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer with peritoneal metastasis: a prospective registry study on 41 patients.
Melissa Ching Ching Teo, Claramae Shulyn Chia, +3 authors, Khee Chee Soo.
Pleura Peritoneum, 2017 Dec 01; 2(4). PMID: 30911648    Free PMC article.
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
Man Yee T Keung, Yanyuan Wu, Jaydutt V Vadgama.
J Clin Med, 2019 Apr 03; 8(4). PMID: 30934991    Free PMC article.
Highly Cited. Review.
PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
Stergios Boussios, Afroditi Karathanasi, +5 authors, Nicholas Pavlidis.
Diagnostics (Basel), 2019 May 22; 9(2). PMID: 31109041    Free PMC article.
Highly Cited. Review.
Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer.
Lawrence B Mensah, Stephen W Morton, +8 authors, Paula T Hammond.
Bioeng Transl Med, 2019 Jun 30; 4(2). PMID: 31249881    Free PMC article.
Recent advancements in PARP inhibitors-based targeted cancer therapy.
Ping Zhou, Justin Wang, Daniel Mishail, Cun-Yu Wang.
Precis Clin Med, 2020 Sep 29; 3(3). PMID: 32983586    Free PMC article.
Review.
Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer.
Marina Pavanello, Isaac Hy Chan, +3 authors, Susan J Ramus.
Cancers (Basel), 2020 Oct 23; 12(10). PMID: 33086730    Free PMC article.
Review.
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications.
Johann S Bergholz, Qiwei Wang, Sheheryar Kabraji, Jean J Zhao.
Clin Cancer Res, 2020 Jun 25; 26(21). PMID: 32576627    Free PMC article.
Review.
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Razan Sheta, Magdalena Bachvarova, +7 authors, Dimcho Bachvarov.
J Transl Med, 2020 Nov 21; 18(1). PMID: 33213473    Free PMC article.
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Alison J Wiggans, Gemma K S Cass, +2 authors, Jo Morrison.
Cochrane Database Syst Rev, 2015 May 21; (5). PMID: 25991068    Free PMC article.
Systematic Review.
Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
Cody J Peer, Jung-Min Lee, +6 authors, William D Figg.
Cancer Chemother Pharmacol, 2017 Jun 04; 80(1). PMID: 28577239    Free PMC article.
Targeting Cancer Stem Cells to Overcome Chemoresistance.
Toni Nunes, Diaddin Hamdan, +10 authors, Anne Janin.
Int J Mol Sci, 2018 Dec 16; 19(12). PMID: 30551640    Free PMC article.
Review.
Genomic loss of heterozygosity and survival in the REAL3 trial.
Elizabeth C Smyth, Catherine Cafferkey, +17 authors, David Cunningham.
Oncotarget, 2019 Jan 08; 9(94). PMID: 30613349    Free PMC article.
Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
Tahira Baloch, Vanessa M López-Ozuna, +5 authors, Walter H Gotlieb.
BMC Cancer, 2019 Jan 12; 19(1). PMID: 30630446    Free PMC article.
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.
Richard Tuli, Stephen L Shiao, +18 authors, Andrew Hendifar.
EBioMedicine, 2019 Jan 13; 40. PMID: 30635165    Free PMC article.
Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer.
Zehua Wang, Jianwen Gao, +2 authors, Congjian Xu.
J Gynecol Oncol, 2019 Feb 12; 30(2). PMID: 30740957    Free PMC article.
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Michael-Antony Lisio, Lili Fu, +2 authors, Carlos Telleria.
Int J Mol Sci, 2019 Mar 01; 20(4). PMID: 30813239    Free PMC article.
Highly Cited. Review.
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Jingyan Yi, Chongya Liu, +9 authors, Hailing Cheng.
EBioMedicine, 2019 Mar 23; 43. PMID: 30898650    Free PMC article.
The role of radiotherapy in epithelial ovarian cancer: a literature overview.
Giuseppe Carlo Iorio, Stefania Martini, +2 authors, Pierfrancesco Franco.
Med Oncol, 2019 Jun 06; 36(7). PMID: 31165334
Review.
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Shaveta Vinayak, Sara M Tolaney, +17 authors, Melinda L Telli.
JAMA Oncol, 2019 Jun 14; 5(8). PMID: 31194225    Free PMC article.
Highly Cited.
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, +22 authors, Pamela Munster.
JAMA Oncol, 2019 Jun 14; 5(8). PMID: 31194228    Free PMC article.
Highly Cited.
Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
Tzu-Ting Huang, Ethan Brill, +5 authors, Jung-Min Lee.
Cancer Res, 2020 Oct 02; 80(23). PMID: 32998994    Free PMC article.
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
Zhimin Zhang, Xiaojuan Lian, +5 authors, Ge Wang.
Sci Rep, 2020 Dec 03; 10(1). PMID: 33262410    Free PMC article.
New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
Ye Han, Xiaopeng Yu, +2 authors, Caigang Liu.
Front Oncol, 2020 Dec 17; 10. PMID: 33324554    Free PMC article.
Review.
Wnts and the hallmarks of cancer.
Zheng Zhong, Jia Yu, David M Virshup, Babita Madan.
Cancer Metastasis Rev, 2020 May 10; 39(3). PMID: 32385713
Review.
Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma.
Dong Li, Chuanfei Hu, +4 authors, Jing Bo Wu.
Int J Nanomedicine, 2020 Dec 18; 15. PMID: 33328733    Free PMC article.
DNA Damage Response in Prostate Cancer.
Matthew J Schiewer, Karen E Knudsen.
Cold Spring Harb Perspect Med, 2018 Mar 14; 9(1). PMID: 29530944    Free PMC article.
Review.
Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.
Virginie Mieulet, Camille Garnier, +7 authors, Fatima Mechta-Grigoriou.
Sci Rep, 2021 Feb 20; 11(1). PMID: 33603134    Free PMC article.
Whole-Genome Sequencing in Cancer.
Eric Y Zhao, Martin Jones, Steven J M Jones.
Cold Spring Harb Perspect Med, 2018 May 31; 9(3). PMID: 29844223    Free PMC article.
Review.
Targeting "undruggable" c-Myc protein by synthetic lethality.
Chen Wang, Hui Fang, Jiawei Zhang, Ying Gu.
Front Med, 2021 Mar 05; 15(4). PMID: 33660217
Review.
p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
Eduardo Cepeda Cañedo, Stephanie Totten, +8 authors, Josie Ursini-Siegel.
JCI Insight, 2021 Jan 21; 6(4). PMID: 33470989    Free PMC article.
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
Zhaozhen Wu, Pengfei Cui, +10 authors, Yi Hu.
Clin Med Insights Oncol, 2021 Mar 20; 15. PMID: 33737855    Free PMC article.
Review.
Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.
Yanyan Jiang, Jennifer Martin, +10 authors, Anderson J Ryan.
Br J Cancer, 2021 Mar 21; 124(11). PMID: 33742147    Free PMC article.
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Camilla Nero, Giuseppe Vizzielli, +5 authors, Claudio Sette.
J Exp Clin Cancer Res, 2021 Apr 02; 40(1). PMID: 33789687    Free PMC article.
Review.
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
Sweta Sharma Saha, Lucy Gentles, +5 authors, Yvette Drew.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33804647    Free PMC article.
DNA Damage Repair Inhibitor for Breast Cancer Treatment.
Ahrum Min, Kyung-Hun Lee, Seock-Ah Im.
Adv Exp Med Biol, 2021 May 14; 1187. PMID: 33983578
CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer.
Ashwini Makhale, Devathri Nanayakkara, +2 authors, Murugan Kalimutho.
Int J Mol Sci, 2021 Jun 03; 22(11). PMID: 34071360    Free PMC article.
Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer.
Chia-Jung Li, Yen-Dun Tony Tzeng, +3 authors, Pei-Yi Chu.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34198652    Free PMC article.
Review.
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.
Emily Hinchcliff, Shannon Neville Westin, +2 authors, Robert L Coleman.
Int J Gynecol Cancer, 2019 May 24;. PMID: 31118216    Free PMC article.
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Hongyan Cheng, Junjun Yang, Huixin Liu, Yang Xiang.
Arch Gynecol Obstet, 2021 May 23; 304(2). PMID: 34021367    Free PMC article.
Systematic Review.
Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.
Justin Zonneville, Moyi Wang, +8 authors, Andrei V Bakin.
Commun Biol, 2021 Jul 14; 4(1). PMID: 34253820    Free PMC article.
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Francesco Schettini, Silvia Paola Corona, +24 authors, Daniele Generali.
Front Oncol, 2021 Jul 16; 11. PMID: 34262869    Free PMC article.
State-of-the-art strategies for targeting the DNA damage response in cancer.
Patrick G Pilié, Chad Tang, Gordon B Mills, Timothy A Yap.
Nat Rev Clin Oncol, 2018 Oct 26; 16(2). PMID: 30356138    Free PMC article.
Highly Cited. Review.
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer.
Michela Palleschi, Gianluca Tedaldi, +3 authors, Ugo De Giorgi.
Int J Mol Sci, 2021 Aug 08; 22(15). PMID: 34360649    Free PMC article.
Review.
Poly(ADP-ribose) polymerase inhibition: past, present and future.
Nicola J Curtin, Csaba Szabo.
Nat Rev Drug Discov, 2020 Sep 05; 19(10). PMID: 32884152
Review.
Breast Cancer Treatments: Updates and New Challenges.
Anna Burguin, Caroline Diorio, Francine Durocher.
J Pers Med, 2021 Aug 28; 11(8). PMID: 34442452    Free PMC article.
Review.
Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma.
Qian Hao, Jiajia Li, +5 authors, Xiang Zhou.
Clin Transl Med, 2021 Aug 31; 11(8). PMID: 34459128    Free PMC article.
Circular RNA: A potential diagnostic, prognostic, and therapeutic biomarker for human triple-negative breast cancer.
Tian Tian, Yangzhi Zhao, +3 authors, Tiejun Wang.
Mol Ther Nucleic Acids, 2021 Sep 14; 26. PMID: 34513294    Free PMC article.
Review.
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
J A Perez-Fidalgo, A Cortés, +10 authors, A González-Martín.
ESMO Open, 2021 Jul 31; 6(4). PMID: 34329939    Free PMC article.
Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
Sayeh Saravi, Zena Alizzi, +2 authors, Emmanouil Karteris.
Cells, 2021 Sep 29; 10(9). PMID: 34572083    Free PMC article.
Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.
Max M Wattenberg, Kim A Reiss.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572943    Free PMC article.
Review.
Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects.
Holger Bronger.
Geburtshilfe Frauenheilkd, 2021 Oct 12; 81(10). PMID: 34629492    Free PMC article.
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
Nicholas C Turner, Judith Balmaña, +27 authors, BRAVO Steering Committee and the BRAVO investigators.
Clin Cancer Res, 2021 Jul 25; 27(20). PMID: 34301749    Free PMC article.
The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Mengyu Tao, Xia Wu.
J Exp Clin Cancer Res, 2021 Oct 28; 40(1). PMID: 34702316    Free PMC article.
Review.
Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
Ying-Cheng Chiang, Po-Han Lin, Wen-Fang Cheng.
Front Oncol, 2021 Nov 02; 11. PMID: 34722237    Free PMC article.
Review.